0000000000213211

AUTHOR

Michael Max Sachse

showing 3 related works from this author

S2k Guidelines for Cutaneous Basal Cell Carcinoma - Part 1: Epidemiology, Genetics and Diagnosis

2018

Basal cell carcinoma is the most common malignant tumor among fair-skinned individuals, and its incidence has been rising steadily in the past decades. In order to maintain the highest quality of patient care possible, the German S2k guidelines were updated following a systematic literature search and with the participation of all professional societies and associations involved in the management of the disease. Part 1 highlights new developments in genetics in particular as well as aspects regarding epidemiology, diagnosis, and histology.

Geneticsmedicine.medical_specialtyMolecular epidemiologybusiness.industryIncidence (epidemiology)MEDLINEDermatologyDiseasemedicine.disease3. Good health030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineEpidemiologymedicineCarcinomaBasal cell carcinomaProfessional associationbusinessJDDG: Journal der Deutschen Dermatologischen Gesellschaft
researchProduct

S2k Guidelines for Cutaneous Basal Cell Carcinoma - Part 2: Treatment, Prevention and Follow-up

2019

Basal cell carcinoma (BCC) is the most common malignant tumor among fair-skinned individuals, and its incidence had been steadily rising in the past decades. In order to maintain the highest quality of patient care possible, the German S2k guidelines were updated following a systematic literature search and with the participation of all professional societies and associations involved in the management of the disease. Part 2 addresses issues such as proper risk stratification, the various therapeutic approaches, and prevention as well as follow-up of patients with basal cell carcinoma.

medicine.medical_specialtybusiness.industryIncidence (epidemiology)MEDLINEDermatologyDiseasemedicine.disease3. Good health030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicinemedicineCarcinomaProfessional associationBasal cell carcinomaDisease management (health)Intensive care medicineRisk assessmentbusinessJDDG: Journal der Deutschen Dermatologischen Gesellschaft
researchProduct

Hematological immune related adverse events after treatment with immune checkpoint inhibitors

2021

Abstract Introduction With the increasing use of checkpoint inhibitors, rare immune-related adverse events (irAE) are being identified. Haematological irAE (hem-irAE) are difficult to treat and have shown high mortality rates. In order to improve side-effect management for these potentially life-threatening events, we analysed frequency, severity and outcomes. Patients and methods Patients who developed hem-irAE while being treated with immune checkpoint inhibitors (ICI) therapy were retrospectively identified from 18 international cancer centres. Results In total, more than 7626 patients treated with ICI were screened, and 50 patients with hem-irAE identified. The calculated incidence amou…

AdultMale0301 basic medicineCancer Researchmedicine.medical_specialtyNeutropeniamedicine.medical_treatmentMedizinNeutropeniamedicine.disease_causeGastroenterologyAutoimmunityYoung Adult03 medical and health sciences0302 clinical medicineImmune systemAdrenal Cortex HormonesInternal medicinemedicineHumansAdverse effectImmune Checkpoint InhibitorsAgedRetrospective StudiesAged 80 and overHemophagocytic lymphohistiocytosisbusiness.industryIncidenceIncidence (epidemiology)CancerAnemiaImmunosuppressionMiddle Agedmedicine.diseaseThrombocytopeniaTreatment Outcome030104 developmental biologyOncology030220 oncology & carcinogenesisFemalebusinessImmunosuppressive Agents
researchProduct